Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



1257 Features
ADHD children not coming to attention of doctors

17 Nov 04

School can be a difficult place at the best of times, however for the 20 million plus children in the seven major pharmaceutical markets that suffer from attention deficit and hyperactivity disorder (ADHD), it can be especially troubling. This exacerbated by the fact that many patients aren't receiving the best available treatment, according to new research from Datamonitor.

Dealing with the urge to merge

15 Nov 04

As pharmaceutical companies attempt to increase productivity and remain financially viable, the prospect of a merger or acquisition is always on the horizon.
Dr Faiz Kermani

Battling against the odds

10 Nov 04

In recent years, the market for those developing new drugs has become much more competitive and the political, regulatory, social and economic pressures more intense.
Dr Faiz Kermani

Hypertension and cardiovascular disease

09 Nov 04

Over the past 30 years, numerous clinical trials evaluating a variety of different classes of drugs have conclusively shown the benefit of blood pressure reduction in reducing the risk of strokes and cardiovascular mortality. Moreover, such trials have clearly demonstrated that blood pressure is unlikely to be controlled with a single drug and often two or more therapies are required to achieve blood pressure targets.
CSF Medical

Double trouble hits Altana respiratory pipeline

05 Nov 04

Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.

The changing face of prostate cancer

04 Nov 04

Prostate cancer is the most common male malignancy in Western countries. Surgery and radiological procedures for localized prostate cancer offer the possibility for curative treatment. Prostate cancer also represents one of the most lucrative oncology indications for the pharmaceutical industry because drug-based treatment is often very effective at delaying disease progression, even in advanced disease, which encourages high-volume and long-term usage. The use of hormonal manipulation for advan

Encouraging Europharma Euphoria

01 Nov 04

The pharmaceutical and biotech industries are important contributors to the economies of European countries and are also major employers. If companies in these sectors are to continue to base themselves in Europe they must be seen as positive forces in the field of technology and healthcare rather than a negative drain on a country's finances.
Dr Faiz Kermani

Biotech and Beyond

29 Oct 04

The environment for drug development is tougher than it has ever been, with companies having to deal with a variety of political, regulatory, social and economic pressures in order to get their products to market. Few biotech companies have been able to devise a strategy to succeed in this hostile environment on their own, but there is no shortage of new entrants in the market.
Dr Faiz Kermani

An insight into hepatocellular carcinoma

29 Oct 04

Hepatocellular carcinoma is the fifth commonest cancer worldwide with about one million new cases diagnosed annually. It is estimated that the incidence of hepatocellular carcinoma in the seven major pharma markets will continue to rise over the next decade. There is no gold standard therapy - the market is characterized by high levels of unmet need, large patient potential and high commercial potential. To mark the publication of its new feature "Hepatocellular Carcinoma" LeadDiscovery's analys

Advances in Translational Research for CNS Diseases

28 Oct 04

Learn about new methods and innovative tools to help you with your translational research.
Jennifer McGinnis

All quiet on the vaccine front?

22 Oct 04

Vaccines represent one of the most effective weapons in the armoury of modern medicine. In an age where the benefits of healthcare interventions in relation to their costs are frequently debated in the media, it is easy to forget the tremendous health contribution that vaccines have made and the millions of lives they have saved.
Dr Faiz Kermani

Accelerating Drug Development and Limiting Failure of Phase I and II Clinical Trials

22 Oct 04

Limitations in the ability to optimize dose modification within the clinical trial setting represents a serious bottleneck in the drug development process. This barrier increases development time, causes the unnecessary early termination of valuable candidates and adds up to $300 million/drug in costs. Petra Biotek are set to knock down these barriers through their computer-based Cycle Dose Modification system. The positive impact that this technology is expected to have on the clinical developm

Cardiovascular risks of HRT confirmed

22 Oct 04

Treatment with combined estrogen/progestin doubles the risk of VTE in post-menopausal women and for obese women the risk is even higher, a recent study showed. However millions of women no longer taking HRT remain at risk of osteoporosis, which presents a huge market opportunity for non-hormonal classes in treating and preventing osteoporosis.

Nexium GP resource provides real value

19 Oct 04

Healthcare professionals in the UK are already experiencing the benefits of being able to view this extensive product and disease-based resource online at a time and place that is convinient to them
Colin Williams

Company profile: Flame Health

18 Oct 04

In 2001, Flame Health was launched in response to the increasing need for an efficient, dedicated recruitment service for the health sector.
Flame Health

Going OTC in the USA

18 Oct 04

The OTC market has become highly competitive for pharmaceutical manufacturers, particularly in the US, which is the largest consumer society in the world. There have been a number of consolidations and acquisitions in the pharmaceutical sector to help companies boost their presence in the OTC field.
Dr Faiz Kermani

Peripheral arterial disease (PAD): A Significant Opportunity for Interventional Therapies

15 Oct 04

Peripheral arterial disease (PAD), caused by systemic atherosclerosis, is vastly underappreciated despite its abysmal mortality rates. With 5 and 10-year rates of 30% and 50% respectively mortality due to PAD is greater than that caused by coronary artery disease and stroke and is exceeded only by colorectal cancer. Better use of the pharmacological and interventional treatments available would dramatically improve the lives of the millions of PAD patients while at the same time ballooning the r

Don’t be scared of Assessment Centres

15 Oct 04

Recruitment is a very inexact science – the statistics in favour of making the right decision based on the traditional interview alone are horrifyingly low (the percentage is in single figures). This is a fact that has really only been acknowledged in recent years and, as a result, organisations have looked for ways to improve the success rate of their selection choices.
Lydia Holder

Flu season begins but a vaccine shortage awaits

14 Oct 04

The recent government suspension of the manufacturing license for major flu vaccine maker Chiron in the UK has left many countries facing a severe shortage in flu vaccine supply for the 2004-05 season. In the light of previous vaccine provision difficulties, Datamonitor's Laura Harris argues that, in the longer term, cell culture vaccines could resolve the annual flu vaccine quandary...

A passage to India?

12 Oct 04

As with other emerging industrial sectors, the Indian pharmaceutical industry has made no secret of its desire to globalise and eventually compete with its foreign rivals.
Dr Faiz Kermani

Outsourcing goes East

12 Oct 04

The conditions for clinical trials are improving in Japan and this has been a factor in the rapid growth of the country's CRO sector.
Dr Faiz Kermani

Life after Vioxx - $2.5 billion up for grabs?

11 Oct 04

Last week, Merck & Co sent shockwaves through the pharmaceutical market with the announcement that it had voluntarily withdrawn its blockbuster arthritis drug Vioxx. Datamonitor's Adele Schulz examines the likely impact of this event, for the remainder of 2004 and beyond, on both Merck and its rivals...

HIV infection - changes in epidemiology driving R&D development and increased market value

07 Oct 04

The demographics of HIV patients are shifting, with the average age of those infected with HIV ever increasing due to longer life expectancy and higher survival rates. However, with increasingly complex infections and drug resistance developing in long term patients, novel medications and new combinations are now being launched to continue the fight...

Therapeutic activity of Bayer's BAY 43-9006 in renal cell carcinoma

05 Oct 04

Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the US and 12,000 patients die of the disease annually. The market is currently dominated by the cytokines, but there is significant interest among physicians in the potential of anti-angiogenics, particularly so since renal cell carcinomas are known to be well vascularized. Bayer's BAY 43-9006 is a

COX-2 withdrawal - Therapeutic, R&D and pharmaceutical impact

01 Oct 04

As the dust settles on Merck's withdrawal of Vioxx's, LeadDiscovery investigates the impact that this will have on the treatment of pain, R&D activity directed towards the identification of new approaches, and on pharmaceutical sales relating to COX-2 inhibitors and related drug classes

New molecular target identified for the prevention of Alzheimer's disease

30 Sep 04

The market for Alzheimer's therapy is expected to grow from 16 million patients to 21 million by 2010 in the seven major pharmaceutical markets. Alzheimer's disease market in the seven major markets is worth $4.7 billion and will increase to $6.1 billion by the year 2005 and $ 7.8 billion by the year 2010. The major unmet need in this market is for disease modification and disease prevention. Recent findings by British researchers showing that targeting the neuronal adaptor protein X11beta can r

Improving levodopa-based complications to advance Parkinson's Disease therapies

29 Sep 04

The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease will lead to an expansion of the already $30 billion neurodegenerative market. Despite the growth of generic products, Parkinson's disease drug revenues grew an impressive 17% across the seven major markets

Probiotic or Conbiotic?

28 Sep 04

Until a few years ago very few people would have given credence to the idea that an ongoing war is being waged in the battleground of the digestive system between good and bad bacteria, but with a marketing onslaught akin to the Star Wars world it parallels the makers of probiotics have now introduced the concept to Britain.
Mark Stacey

Unlocking China’s Pharma Potential

24 Sep 04

China is predicted to be a major pharmaceutical market in the future. However, like other emerging markets, there are a number of challenges that companies need to deal with in order to unlock its full potential.
Dr Faiz Kermani

Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil demonstrates antiinflammatory activity in hypertensive patients.

22 Sep 04

Earlier this year data was reported that Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil may offer improved anti-hypertensive activity when compared to other therapeutic agents within this highly competitive $31 billion market. More recently clinical data has appeared that shows olmesartan to have additional anti- inflammatory activity in hypertensive patients with vascular inflammation. This may confer additional therapeutic benefit since inflammation is an etiological compo

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.